| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/21/2002 | WO2002014270A1 New amidino derivatives and their use as thrombin inhibitors |
| 02/21/2002 | WO2002014269A2 2,4-substituted pyridine derivatives |
| 02/21/2002 | WO2002014267A1 Novel aminocyclohexane derivatives |
| 02/21/2002 | WO2002014265A1 Novel 3-substituted urea derivatives and medicinal use thereof |
| 02/21/2002 | WO2002014264A2 (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production |
| 02/21/2002 | WO2002014252A2 Compositions containing hypoglycemically active stilbenoids |
| 02/21/2002 | WO2002014251A1 Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
| 02/21/2002 | WO2002013882A1 Implants with a phosphazene-containing coating |
| 02/21/2002 | WO2002013873A2 P97-active agent conjugates and their methods of use |
| 02/21/2002 | WO2002013870A2 Formulation for administering therapeutic lipophilic molecules |
| 02/21/2002 | WO2002013868A1 Dermatological formulation |
| 02/21/2002 | WO2002013867A2 Augmented cognitive training |
| 02/21/2002 | WO2002013866A2 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/21/2002 | WO2002013855A2 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | WO2002013854A1 Obesity controlling method |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013843A2 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| 02/21/2002 | WO2002013842A1 Compositions comprising icariside i and anhydroicaritin and methods for making the same |
| 02/21/2002 | WO2002013833A2 SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 |
| 02/21/2002 | WO2002013832A1 Remedial agent for osteoporosis |
| 02/21/2002 | WO2002013831A1 Use of triazinetrione sulfoxides for controlling coccidioses |
| 02/21/2002 | WO2002013829A1 Compositions containing an inhibitor of dihydrofolate reductase and a folate |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013827A1 Process for the preparation of dinapsoline |
| 02/21/2002 | WO2002013826A1 Anti-cancer composition composed of anti-cancer and anti-malarial drugs |
| 02/21/2002 | WO2002013825A1 Novel pharmaceutical use of quinnoline derivatives |
| 02/21/2002 | WO2002013824A1 Cyclopentyl modulators of chemokine receptor activity |
| 02/21/2002 | WO2002013823A1 Micronized torsemide |
| 02/21/2002 | WO2002013821A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | WO2002013820A1 Photosensitizing ointment |
| 02/21/2002 | WO2002013819A1 Seamless soft capsule preparations containing dihydrobenzofuran derivatives |
| 02/21/2002 | WO2002013818A1 Treating sickle cell disease |
| 02/21/2002 | WO2002013817A1 Remedies for cisplatin-tolerant cancer |
| 02/21/2002 | WO2002013816A1 Pharmaceutical composition |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013814A1 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders |
| 02/21/2002 | WO2002013813A1 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders |
| 02/21/2002 | WO2002013812A1 Methods for treating inflammatory diseases |
| 02/21/2002 | WO2002013810A1 Water-soluble prodrugs of propofol for treatment of migraine |
| 02/21/2002 | WO2002013809A2 Compositions containing hypotriglyceridemically active stilbenoids |
| 02/21/2002 | WO2002013808A2 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | WO2002013807A2 Compounds for the treatment of addictive disorders |
| 02/21/2002 | WO2002013806A2 Compositions containing hypotriglyceridemically active stilbenoids |
| 02/21/2002 | WO2002013805A2 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 02/21/2002 | WO2002013804A2 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid |
| 02/21/2002 | WO2002013802A2 Method of treating estrogen receptor positive carcinoma |
| 02/21/2002 | WO2002013801A2 Method of treating the syndrome of coronary heart disease risk factors in humans |
| 02/21/2002 | WO2002013800A2 Method for the prevention and treatment of retinopathy |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013797A2 Therapeutic combination of a cetp inhibitor and atorvastatin |
| 02/21/2002 | WO2002013796A2 Use of proton pump inhibitors for treating diseases of the locomotor system |
| 02/21/2002 | WO2002013793A2 Method of making tablets and tablet compositions produced therefrom |
| 02/21/2002 | WO2002013791A2 Steroid hormones as transfer agents |
| 02/21/2002 | WO2002013790A1 Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| 02/21/2002 | WO2002013789A1 Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine] |
| 02/21/2002 | WO2002013788A1 Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
| 02/21/2002 | WO2002013766A2 Valproic acid derivatives for the treatment of pain |
| 02/21/2002 | WO2002013764A2 Methods for treating subjects infected with a herpes virus or neisseria gonorrheae |
| 02/21/2002 | WO2002013759A2 Method of treating the syndrome of type 2 diabetes in humans |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001089482A3 Method for preparing microparticles having a selected polymer molecular weight |
| 02/21/2002 | WO2001085668A8 Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001082873A3 A medicinal aerosol formulation |
| 02/21/2002 | WO2001082863A3 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 02/21/2002 | WO2001081328A3 Thiazolidinedione analogues and their use for the treatment of diabetes |
| 02/21/2002 | WO2001080837A3 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 02/21/2002 | WO2001080619A3 Pharmaceutical composition containing citalopram |
| 02/21/2002 | WO2001079196A3 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076601A3 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 02/21/2002 | WO2001076554A3 Drug delivery composition and device |
| 02/21/2002 | WO2001074315A3 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| 02/21/2002 | WO2001074314A3 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 02/21/2002 | WO2001074313A3 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001072291A3 Treatment of movement disorders with metabotropic glutamate receptor antagonist |
| 02/21/2002 | WO2001068609B1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 02/21/2002 | WO2001068065A3 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066597A3 Inflammation-related gene |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001064246A3 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 02/21/2002 | WO2001058869B1 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 02/21/2002 | WO2001055391A3 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001054654A3 Reduction of hair growth |
| 02/21/2002 | WO2001052817A3 Cochleate formulations and their use for delivering biologically relevant molecules |
| 02/21/2002 | WO2001049703A3 Substituted sapogenins and their use |
| 02/21/2002 | WO2001047510A3 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 02/21/2002 | WO2001045717A3 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 02/21/2002 | WO2001045671A3 Suspension comprising oxcarbazepine |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001042225A3 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 02/21/2002 | WO2001041755A3 Topical compositions comprising thalidomide for the treatment of inflammatory diseases |
| 02/21/2002 | WO2001037812A3 Gastroretentive controlled release pharmaceutical dosage forms |
| 02/21/2002 | WO2001032631A3 Heterocyclic cytotoxic agents |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030323A3 Controlled-release biocompatible ocular drug delivery implant devices and methods |